Antitumour efficacy of TRAIL: an immunotherapeutic approach for the treatment of skeletal malignancies

实体瘤患者最严重的临床问题是骨转移，这会导致并发症，影响患者的生活质量，最终导致死亡。TRAIL是一种新的癌症治疗方法，可以选择性地杀死癌细胞，同时保留正常细胞。使用不结合OPG且血清半衰期延长的TRAIL激动抗体为治疗骨骼恶性肿瘤提供了一种无毒且安全的令人兴奋的方法。

The most serious clinical problem with patients with solid tumours is metastasis to bone, which leads to complications that can cause erosion of the patient's quality of life, and eventually death. TRAIL is a new cancer therapeutic that selectively kills cancer cells while sparing normal cells. The use of TRAIL agonistic antibodies that do not bind OPG and have increased serum half life offers an exciting approach for the treatment of skeletal malignancies that is non toxic and safe.